- Home
- NRIX vs MANE Comparison
NRIX vs MANE Comparison
Compare NRIX & MANE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRIX | MANE |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | NRIX | MANE |
|---|---|---|
| Price | $17.75 | $100.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $30.50 | ★ $83.33 |
| AVG Volume (30 Days) | ★ 874.4K | 533.6K |
| Earning Date | 04-08-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $76,987,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 99.31 | N/A |
| 52 Week Low | $8.20 | $36.26 |
| 52 Week High | $22.50 | $117.71 |
Technical Indicators
Market Signals| Indicator | NRIX | MANE |
|---|---|---|
| Relative Strength Index (RSI) | 63.12 | 54.47 |
| Support Level | $17.21 | $95.70 |
| Resistance Level | $19.98 | $117.71 |
| Average True Range (ATR) | 0.80 | 7.01 |
| MACD | 0.17 | -1.90 |
| Stochastic Oscillator | 88.45 | 34.46 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About MANE Veradermics Incorporated Common Stock
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.